Gear Up for ChargePoint (CHPT) Q4 Earnings: Wall Street Estimates for Key Metrics
ZACKS· 2026-02-27 15:15
Core Viewpoint - ChargePoint Holdings, Inc. (CHPT) is expected to report a quarterly loss of -$1.07 per share, which is a 10.8% increase compared to the same period last year, with revenues forecasted at $104.61 million, reflecting a year-over-year increase of 2.7% [1] Group 1: Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1] - Changes in earnings estimates are crucial for predicting potential investor reactions to the stock [2] Group 2: Key Metrics Projections - Analysts project 'Networked charging systems' revenue to reach $55.13 million, indicating a year-over-year change of +4.8% [4] - The average estimate for 'Subscriptions' is $42.60 million, reflecting an increase of +11.3% from the prior-year quarter [4] - The consensus for 'Other' revenue is expected to be $7.33 million, suggesting a year-over-year decline of -33.4% [4] Group 3: Stock Performance - ChargePoint shares have increased by +4.6% over the past month, contrasting with the Zacks S&P 500 composite's decline of -0.5% [4] - ChargePoint holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [4]
Countdown to Okta (OKTA) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
ZACKS· 2026-02-27 15:15
In its upcoming report, Okta (OKTA) is predicted by Wall Street analysts to post quarterly earnings of $0.85 per share, reflecting an increase of 9% compared to the same period last year. Revenues are forecasted to be $749.1 million, representing a year-over-year increase of 9.8%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earn ...
What Analyst Projections for Key Metrics Reveal About Genius Sports Limited (GENI) Q4 Earnings
ZACKS· 2026-02-27 15:15
Wall Street analysts expect Genius Sports Limited (GENI) to post quarterly earnings of $0.02 per share in its upcoming report, which indicates a year-over-year increase of 166.7%. Revenues are expected to be $235.52 million, up 34.2% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 17.6% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course ...
Exploring Analyst Estimates for American Eagle (AEO) Q4 Earnings, Beyond Revenue and EPS
ZACKS· 2026-02-27 15:15
In its upcoming report, American Eagle Outfitters (AEO) is predicted by Wall Street analysts to post quarterly earnings of $0.71 per share, reflecting an increase of 31.5% compared to the same period last year. Revenues are forecasted to be $1.73 billion, representing a year-over-year increase of 7.9%.The current level reflects an upward revision of 60% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised the ...
Telsey Advisory Raises TJX Outlook on Strength despite Ongoing Macro Pressures
Yahoo Finance· 2026-02-27 15:15
The TJX Companies, Inc. (NYSE:TJX) is included among the 13 Best Long-Term Dividend Stocks to Invest in Right Now. Telsey Advisory Raises TJX Outlook on Strength despite Ongoing Macro Pressures On February 26, Telsey Advisory raised its price target on The TJX Companies, Inc. (NYSE:TJX) to $175 from $170. The firm kept an Outperform rating on the shares. The analyst said the company delivered another strong quarter and continues to perform well, even with ongoing macro uncertainty. TJX has managed to sta ...
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Businesswire· 2026-02-27 15:15
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE- B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer re ...
Sunrun Stock Falls 30% As Growth Metrics Disappoint
Benzinga· 2026-02-27 15:14
Sunrun Inc (NASDAQ:RUN) shares are trading sharply lower Friday after the solar and storage provider posted fourth-quarter results after the bell Thursday that topped Wall Street forecasts but highlighted slower growth. Here’s what investors need to know.Sunrun shares are sliding. Why is RUN stock dropping?Q4 Earnings And Sales Beat EstimatesThe company reported adjusted fourth-quarter earnings of 38 cents per share, smashing analyst expectations for a loss of 8 cents, though profits fell sharply from $1.41 ...
Shareholder Alert: The Ademi Firm investigates whether KORE Group Holdings Inc. is obtaining a Fair Price for its Public Shareholders
Prnewswire· 2026-02-27 15:14
Shareholder Alert: The Ademi Firm investigates whether KORE Group Holdings Inc. is obtaining a Fair Price for its Public Shareholders [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 27, 2026 /PRNewswire/ -- Ademi LLP is investigating KORE (NYSE: KORE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Searchlight Capital Partners and Abry Partners.Click [here] to learn how to join our investigation and obtain additional information or cont ...
O’Reilly Automotive (ORLY) is Accelerating New Store Openings in 2026
Yahoo Finance· 2026-02-27 15:13
Aristotle Funds, an investment advisor, released its “Core Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10%. Within the Russell 1000 Growth Index, healthcare, communication services, and financials were the top performing sectors, while utilities, real estate, and materials lagged. The U.S. economy showed ...
Telsey Advisory Raises Lowe’s (LOW) Outlook on Solid Demand and Execution Strength
Yahoo Finance· 2026-02-27 15:13
Lowe’s Companies, Inc. (NYSE:LOW) is included among the 13 Best Long-Term Dividend Stocks to Invest in Right Now. Telsey Advisory Raises Lowe’s (LOW) Outlook on Solid Demand and Execution Strength Copyright: luckydog / 123RF Stock Photo On February 26, Telsey Advisory analyst Joseph Feldman raised the price recommendation on Lowe’s Companies, Inc. (NYSE:LOW) to $295 from $285. He reiterated an Outperform rating on the stock. The analyst said the company delivered better-than-expected Q4 results, with de ...